20241028-万联证券-润本股份-603193.SH-点评报告_Q3归母净利润快速增长_盈利能力同比提升明显_3页_785kb

Section: Company Performance Summary

Q3 Financial Highlights:
For the third quarter of 2024, [Runben Pharmaceutical Co., Ltd., Code: 603193] reported a significant increase in both revenue and net profit attributable to shareholders, achieving +2010% and +3198% year-over-year growth, respectively. This trend continued from Q1-Q3, where revenue were approximately 10.13 billion yuan (+2598% YoY), net profit attributable to shareholders was around 2.61 billion yuan (+4435% YoY), and earnings before tax rose sharply by +4445% YoY.

Profitability Improvement:
Net profit margin showed a substantial improvement, reaching 2.515% in Q3, a +320 percentage points increase YoY. Gross margin also saw a dramatic rise of +221 percentage points to 58.33% YoY. This significant improvement in profitability, however, was accompanied by an increased sales expense ratio. Financial performance indicators across the period showed mixed changes in operating expenses; for instance, the management and R&D expense ratios decreased slightly, while the finance expense ratio dropped notably. The overall financial health and operational outcomes appeared to be strengthened during the reviewed period.

Product Performance Insights:
Q3 performance indicated robust sales for key product categories. Specifically, the mosquito repellent, childcare and essential oil product lines saw compelling growth rates of +1615%, +2672%, and +1535% YoY respectively. Notably, the average selling prices for these three product lines increased collectively. Among them, the essential oil segment demonstrated the highest price increase, with an average selling price growth rate of +1405%. This is attributed to increasing sales volume and the higher price point of premium essential oil products, which subsequently rose in their revenue contribution.

Company Strategy & Future Outlook:
The company, specializing in mosquito repellents and personal care, has cultivated a strong reputation over two decades. It attributes its current standing partly to internal production capabilities creating a supply chain edge, and operational efficiencies from streamlined management. Products secure market acceptance while maintaining quality under a cost-competitive framework. Anticipating further growth drivers from innovative R&D efforts and product launches, the company's earnings prognosis remains positive.

Investment Recommendation:
Maintaining a 'Buy' recommendation based on the review of historical results and future outlook. The financial projections for 2024-2026 project EPS increasing from 0.73 to 1.12 yuan per share, supporting valuation multiples (P/E ratios) that are expected to tighten from 33x to 22x relative to 2024E. The company’s operational performance and growth trajectory are considered favorable, offering a key investment narrative.

Risks:
Potential risks include macroeconomic fluctuations, consumer spending uncertainties, increased industry competition, slower-than-anticipated market expansion for new products, and concentration risk in sales channels. While short-term financial figures are encouraging, these external and operational factors warrant monitoring.